Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31091 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Olayinka Okeleji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Hodgkin Disease, Nivolumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
To the Editor: Combination chemotherapy and radiation therapy have been the standard treatment of classical Hodgkin lymphoma (cHL) in pediatric patients, achieving a 5-year overall survival (OS) rate of 95%.1, 2 Over the past decade, two notable targeted therapeutics (brentuximab vedotin [BV] and nivolumab) have gained U.S. Food and Drug Administration approval for newly diagnosed and relapsed/refractory cHL, respectively.3, 4 These two agents have been studied with different chemotherapy backbones, but most recently, AVD (doxorubicin, vinblastine, and dacarbazine). BV, a CD30 targeted antibody–drug conjugate, and nivolumab, an anti-PD-1 antibody, when combined with AVD, have excellent efficacy (86% and 94% progression-free survival [PFS], respectively) and safety profiles in adult and pediatric patients with newly diagnosed cHL.5 BV–AVD plus radiation has also been employed in frontline settings for early-stage unfavorable cHL, producing promising results with four cycles, with a 1-year PFS of 93%. Using these data to guide management, we describe three pediatric patients (age 12 years old) in the recent SouthWest Oncology Group (SWOG) 1826 study, incorporation of these novel agents with a more traditional adult chemotherapy backbone for younger children (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Olayinka Okeleji, Amber Gibson, Miriam B Garcia, Michael Roth, David McCall
Zitieren
APA
Okeleji, O., Gibson, A., Nunez, C., Garcia, M. B., Roth, M., Cuglievan, B., & McCall, D. (2024). Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31091
Vancouver
Okeleji O, Gibson A, Nunez C, Garcia MB, Roth M, Cuglievan B, et al. Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31091
BibTeX
@article{Okeleji2024,
author = {Okeleji, Olayinka and Gibson, Amber and Nunez, Cesar and Garcia, Miriam B and Roth, Michael and Cuglievan, Branko and McCall, David},
title = {Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31091}
}
EUVIMED